Global RNA-based Therapeutics Drug Supply, Demand and Key Producers, 2023-2029

Global RNA-based Therapeutics Drug Supply, Demand and Key Producers, 2023-2029

The global RNA-based Therapeutics Drug market size is expected to reach $ 84010 million by 2029, rising at a market growth of 3.6% CAGR during the forecast period (2023-2029).

The Nucleic Acid-Based Therapeutics Drug Market is driven by the promising potential of nucleic acid-based therapies in treating various genetic and acquired diseases, including genetic disorders, cancer, and infectious diseases. These innovative drugs utilize nucleic acids, such as DNA or RNA, to modify or regulate gene expression, correct genetic mutations, or target specific disease-associated genes. As the understanding of genomics and molecular biology advances, and personalized medicine gains traction, the demand for nucleic acid-based therapeutics continues to grow. Innovations in drug development, delivery systems, and gene editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to address delivery and stability issues, ensure long-term safety and efficacy, and navigate regulatory complexities and patient acceptance. Overcoming technical and scientific hurdles, optimizing drug delivery methods, and addressing concerns about off-target effects are ongoing challenges. Additionally, the market faces competition from conventional therapies and the need for continuous research and development to unlock the full therapeutic potential of nucleic acid-based drugs. Striking a balance between providing safe, effective, and accessible nucleic acid-based therapeutics while addressing scientific and regulatory challenges is essential for the continued growth of the Nucleic Acid-Based Therapeutics Drug Market.

Nucleic acid drugs, also known as nucleic acid-based therapeutics, are a class of pharmaceuticals designed to treat various diseases by targeting specific genes or genetic processes within the human body. They are distinct from traditional small molecule drugs and instead rely on nucleic acids, which are the building blocks of genetic information. Nucleic acid drugs encompass various types of pharmaceuticals that use nucleic acids, such as DNA or RNA, as their active components to target specific genes or genetic processes.

This report studies the global RNA-based Therapeutics Drug demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for RNA-based Therapeutics Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of RNA-based Therapeutics Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global RNA-based Therapeutics Drug total market, 2018-2029, (USD Million)

Global RNA-based Therapeutics Drug total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: RNA-based Therapeutics Drug total market, key domestic companies and share, (USD Million)

Global RNA-based Therapeutics Drug revenue by player and market share 2018-2023, (USD Million)

Global RNA-based Therapeutics Drug total market by Type, CAGR, 2018-2029, (USD Million)

Global RNA-based Therapeutics Drug total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global RNA-based Therapeutics Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech and Pfizer, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World RNA-based Therapeutics Drug market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global RNA-based Therapeutics Drug Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global RNA-based Therapeutics Drug Market, Segmentation by Type
Antisense Oligonucleotides (ASO)
siRNA
mRNA

Global RNA-based Therapeutics Drug Market, Segmentation by Application
Neuromuscular Diseases
hATTR
COVID-19
Other

Companies Profiled:
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna

Key Questions Answered

1. How big is the global RNA-based Therapeutics Drug market?

2. What is the demand of the global RNA-based Therapeutics Drug market?

3. What is the year over year growth of the global RNA-based Therapeutics Drug market?

4. What is the total value of the global RNA-based Therapeutics Drug market?

5. Who are the major players in the global RNA-based Therapeutics Drug market?